Last C$1.18 CAD
Change Today +0.05 / 4.42%
Volume 117.7K
BTI On Other Exchanges
As of 3:35 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

bioasis technologies inc (BTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/14/14 - C$1.35
52 Week Low
10/15/14 - C$0.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bioasis technologies inc (BTI) Related Businessweek News

No Related Businessweek News Found

bioasis technologies inc (BTI) Details

biOasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing Transcend and Transcend pep platforms for the transport of therapeutic agents across the blood brain barrier for the treatment of brain cancer, tumors, neurodegenerative diseases, metabolic diseases, small-interfering RNA gene therapy, and stroke and traumatic brain injury. The company owns approximately 30 U.S. and foreign patents/applications related to p97 as a blood-brain barrier delivery vector and as a biomarker for Alzheimer's disease. It has collaboration agreements with Shire Human Genetic Therapies Inc., AbbVie Inc., Medimmune Limited, and UCB Pharma SA. The company was incorporated in 2006 and is headquartered in Richmond, Canada.

Founded in 2006

bioasis technologies inc (BTI) Top Compensated Officers

Founder, Chairman, President and Chief Execut...
Total Annual Compensation: C$166.0K
Compensation as of Fiscal Year 2014.

bioasis technologies inc (BTI) Key Developments

biOasis Technologies Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

biOasis Technologies Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

biOasis Technologies Inc. Advances MPS II Study with Renowned Lysosomal Storage Disease

biOasis Technologies Inc. announced a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the 'Diagnosis and Therapy of Lysosomal Disorders' research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin. The human enzyme to be administered in the study, Idursulfase (I2S), is missing or functionally deficient in human sufferers of Hunter Syndrome. The study will use a knockout animal model that has shown the same characteristics as in the human form of MPS II. The study will demonstrate whether a therapeutic quantity of I2S can be delivered in the animal's brain using biOasis' fusion proteins, MTf-I2S and the Transcend peptide-based MTfp-I2S, and whether the proteins can restore normal I2S function after intravenous administration. Through the mechanism of Receptor Mediated Transcytosis, the biOasis fusion proteins, MTfp-I2S and MTf-I2S, are designed to cross the BBB and to allow the I2S to localize in the lysosomes of brain cells. The study will allow biOasis and B4B to not only study the effects of the fusion MTfp and MTf proteins on the restoration of enzymatic activity, but also the effect of the proteins' administration in brain parenchyma cells and in cells from various other tissues. Preliminary experiments using this animal model of MPS II have suggested that Enzyme Replacement Therapy with recombinant I2S may be effective in reducing the build-up of GAG stores that result from the I2S enzyme deficiency. The results of the study will be used to support the design of clinical studies to evaluate the efficacy of MTfp-I2S and MTf-I2S in MPS II patients.

biOasis Technologies Inc. Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease

biOasis Technologies Inc. announced the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC"), will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcendpep, to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme -hexosaminidase subunit beta ("HEXB"), which is functionally deficient in sufferers of Sandhoff Disease. The colony of HEXB-deficient animals that populate the "knockout" model have been under development for several months in the UBC laboratory of biOasis' founding scientist, Dr. Wilfred Jefferies of the University's renowned Michael Smith Laboratories. The animals will undergo six weeks of treatment with biOasis' proprietary therapeutics, fMTf-HEXB, a fusion protein consisting of Transcend and -hexosaminidase subunit beta, and fMTfp-HEXB, a fusion protein consisting of Transcendpep and -hexosaminidase subunit beta. The treatment period will commence in October when the colony's age and weight are ideal for treatment. This is the first study where biOasis is utilizing fusion protein versions of its platform technologies. Both fMTf-HEXB and fMTfp-HEXB are classified as chimeric fusion proteins, hybrid proteins that are made of polypeptides that have varying functions or physico- chemical patterns. In the past, biOasis has used chemical conjugation methods to produce therapeutics for test purposes. The method was used because it is faster and less expensive for "proof of concept" purposes. However, chemical conjugations generally do not produce consistent molecular structures. biOasis' chimeric fusion proteins are designed to guarantee that each therapeutic is produced in a structurally consistent manner and that the binding sites of the respective Transcend and Transcendpep molecules are not masked, theoretically enhancing both the binding activity and the transport of therapeutics across the Blood- Brain Barrier.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTI:CN C$1.18 CAD +0.05

BTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTI.
View Industry Companies

Industry Analysis


Industry Average

Valuation BTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 17.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOASIS TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at